PRINCETON, N.J., June 2, 2011 /PRNewswire/ — Soligenix,
Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company, announced today that it recently
appointed Joseph Warusz as its new Vice President of Administration
and Controller. In this role, Mr. Warusz will oversee the
Accounting, Human Resources, and Administrative functions, as well
as serve as the Company’s Principal Accounting Officer for SEC
reporting purposes.
Mr. Warusz comes to Soligenix with more than 28 years of
financial management experience in public and private life science
companies as well as large pharma. Prior to joining Soligenix, he
held senior financial positions with Amicus Therapeutics, Inc.,
Orchid Cellmark, Inc., and NexMed, Inc., as well as consulting
assignments at Ardea BioSciences, Inc., and NovaDel Pharma, Inc.,
all R&D-focused companies in the biotechnology and specialty
pharmaceuticals arenas. Prior to 1998, Mr. Warusz also held
management positions in financial analysis, accounting, reporting
and auditing at Bristol-Myers Squibb and Peat Marwick Main &
Company. He received his BS in accounting and MBA in finance at
Drexel University and was a Certified Public Accountant previously
licensed in the State of Pennsylvania.
“I am very excited to be joining Soligenix at this point in its
development and I look forward to contributing to the company’s
continued growth in 2011 and beyond,” stated Mr. Warusz.
“We are very pleased to welcome Joseph to the Soligenix team,”
said Evan Myrianthopoulos, Chief Financial Officer of Soligenix.
“His experience with development stage and commercial biotech and
pharmaceutical companies will serve us well as we diligently work
to complete our confirmatory Phase 3 clinical trial of orBec®
in the treatment of acute GI GVHD.”
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company developing
products to treat life-threatening side effe
‘/>”/>
